T-Cell Modulatory Polypeptides and KRAS Peptide Cancer Treatment Methods
Summary
USPTO published patent application US20260109958A1 by inventors Chee Meng Low and Ahmet Selim Vakkasoglu on April 23, 2026, covering T-cell modulatory polypeptides (TMPs) comprising a KRAS peptide linked to class I MHC polypeptides, fusion molecules with heterologous partners, and single-chain immunomodulatory constructs with Ig Fc or non-Ig scaffolds. The application claims compositions and methods for modulating T-cell activity and treating KRAS-associated cancers including lung, colorectal, and pancreatic cancers. Filing date was December 16, 2025, under application number 19422115.
“A TMP is useful for modulating the activity of a T cell, for modulating an immune response in an individual, and/or for treating an individual who has a KRAS-associated cancer.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
USPTO published Application US20260109958A1 disclosing peptide-major histocompatibility complex (pMHC) polypeptides incorporating KRAS peptides and class I MHC components, along with fusion molecules and single-chain TMPs designed to modulate immune responses against KRAS-mutant cancers. The claimed compositions include an immunoglobulin Fc region or non-Ig scaffold as structural elements.
Competitors developing KRAS-targeted cancer immunotherapies should review freedom-to-operate implications, as this application discloses a broad class of pMHC-based T-cell modulatory constructs with therapeutic applications. The inventors' modular approach (pMHC plus immunomodulatory polypeptide plus scaffold) may cover multiple commercial configurations beyond standalone KRAS peptide therapeutics.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
T-Cell Modulatory Polypeptides and Methods of Use Thereof
Application US20260109958A1 Kind: A1 Apr 23, 2026
Inventors
Chee Meng Low, Ahmet Selim Vakkasoglu
Abstract
The present disclosure provides a peptide-major histocompatibility complex (pMHC) polypeptide comprising a KRAS peptide and class I MHC polypeptides. The present disclosure provides fusion molecules comprising a pMHC polypeptide and a heterologous fusion partner. The present disclosure provides single-chain T-cell modulatory polypeptides that comprise a pMHC polypeptide, one or more immunomodulatory polypeptide, and an immunoglobulin (Ig) Fc or a non-Ig scaffold. A TMP is useful for modulating the activity of a T cell, for modulating an immune response in an individual, and/or for treating an individual who has a KRAS-associated cancer.
CPC Classifications
C12N 9/14 C07K 14/55 C07K 14/70503 C07K 14/70539 C07K 16/2818 C07K 16/2827 A61K 38/00 C07K 2317/569 C07K 2317/622 C07K 2319/30 C12Y 306/05002
Filing Date
2025-12-16
Application No.
19422115
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.